Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
about
Platelet-related phenotypic patterns in hepatocellular carcinoma patients.Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation studyGALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma.Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma.Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.Chemoembolization and radioembolization for hepatocellular carcinoma.Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.Update on biomarkers of hepatocellular carcinoma.Hepatocellular carcinoma: systemic therapies and future perspectives.Hepatic imaging following intra-arterial embolotherapy.Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma.Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.A long-term follow-up and comprehensive observation of risk and prognosis factors of recurrence and survival after resection of hepatocellular carcinoma.Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.Changes of alpha-fetoprotein levels could predict recurrent hepatocellular carcinoma survival after trans-arterial chemoembolization.The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma.Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib.Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma.HCC with low- and normal-serum alpha-fetoprotein levels.[Selective internal radioembolization in nonresectable hepatocellular carcinoma].Response stratification and survival analysis of hepatocellular carcinoma patients treated with intra-arterial therapy using MR imaging-based arterial enhancement fraction.Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.Percutaneous Treatment of Localized Infiltrative Hepatocellular Carcinoma Developing on Cirrhosis.Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know.Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection.Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
P2860
Q33416416-F058BE3C-7982-4262-A056-0360F8A6A9F3Q33441170-95B32942-7DEC-42C0-B431-C8BC23B603AFQ33733830-F476BB8C-96A9-4842-8E6A-7DB9C0B20D26Q34550662-96EB21B8-30BE-4679-875A-4AE459DA20F2Q35739788-94EBB8FF-6F52-4E14-BC7B-46A02998B25CQ36639895-86EC3042-AAEA-4247-9E13-AF07D1F785D2Q37238192-A3920023-C5D5-4E03-9E47-21EA08B36852Q37396802-512564BB-B4CB-435B-9420-C517ACAB1410Q38166133-7BD8F58C-5514-428C-B9CD-91B76A6503C1Q38246965-32EDB87A-6E0D-4A46-B347-17CBBB4CAADFQ38716483-27142787-D3EE-4BA6-9C78-290E95A27215Q40582565-A5D67025-AAD9-4642-AF6D-C4D1FE42D7F1Q41235807-9D3ABEAA-5051-4651-BA49-650C36D19A5CQ42224788-55138CB6-31AE-4C35-89F3-226BC4751F83Q43470197-2ADE9344-9D3D-48CD-AC4F-64299452239FQ45385200-0E096FF2-794E-417D-9B90-35B604A1E369Q46455135-3445666D-E930-4E66-B047-B0ECAA9CADD4Q47106977-32CF657C-26C9-4212-92A8-B33A0C33741CQ48285755-FDBA2ACF-4C0C-4553-88C0-E5550A543368Q52632547-92787B4A-13BA-4660-B496-5795F03D0CEDQ53061048-B0A42DE3-3DCC-4D3D-9D96-8FC4FB2DCC6CQ53089236-E13A89AC-541B-45D0-9ECC-339353F63A42Q53147159-3545F88E-94B7-45B5-B3BE-4D5BDDA3F54EQ53220257-84E8D70E-DCF0-475C-BBA0-924FE9EBB540Q55283883-5546E975-A8BA-4290-A83B-5CAE68F6CB51Q55505675-838E3165-D9F1-435B-9AB6-DE541262CF0DQ56374228-C60A80F2-9ACE-4584-82D8-E610DEDA6954
P2860
Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Alpha-fetoprotein response cor ...... herapies: a subgroup analysis.
@ast
Alpha-fetoprotein response cor ...... herapies: a subgroup analysis.
@en
type
label
Alpha-fetoprotein response cor ...... herapies: a subgroup analysis.
@ast
Alpha-fetoprotein response cor ...... herapies: a subgroup analysis.
@en
prefLabel
Alpha-fetoprotein response cor ...... herapies: a subgroup analysis.
@ast
Alpha-fetoprotein response cor ...... herapies: a subgroup analysis.
@en
P2093
P2860
P1476
Alpha-fetoprotein response cor ...... herapies: a subgroup analysis.
@en
P2093
Ahsun Riaz
Al B Benson
Edward Wang
Frank H Miller
Khairuddin Memon
Laura Kulik
Mary F Mulcahy
Michael Abecassis
Paul Nikolaidis
Reed A Omary
P2860
P304
P356
10.1016/J.JHEP.2011.11.020
P577
2012-01-13T00:00:00Z